I-131-MIBG therapies

S. Voo, J. Bucerius, F.M. Mottaghy

Research output: Contribution to journalArticleAcademicpeer-review

7 Citations (Scopus)

Abstract

Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. Extensive work has been addressed to develop I-131-MIBG therapy: doses, therapeutic schemes, and efficiency. In this paper, we present an overview on I-131-MIBG therapy, with main focus on different aspects how to perform this treatment.
Original languageEnglish
Pages (from-to)238-45
JournalMethods
Volume55
Issue number3
DOIs
Publication statusPublished - 1 Jan 2011

Cite this

Voo, S. ; Bucerius, J. ; Mottaghy, F.M. / I-131-MIBG therapies. In: Methods. 2011 ; Vol. 55, No. 3. pp. 238-45.
@article{7800c4a9dd294405a28191365cac04b9,
title = "I-131-MIBG therapies",
abstract = "Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. Extensive work has been addressed to develop I-131-MIBG therapy: doses, therapeutic schemes, and efficiency. In this paper, we present an overview on I-131-MIBG therapy, with main focus on different aspects how to perform this treatment.",
author = "S. Voo and J. Bucerius and F.M. Mottaghy",
year = "2011",
month = "1",
day = "1",
doi = "10.1016/j.ymeth.2011.10.006",
language = "English",
volume = "55",
pages = "238--45",
journal = "Methods",
issn = "1046-2023",
publisher = "Elsevier Science",
number = "3",

}

I-131-MIBG therapies. / Voo, S.; Bucerius, J.; Mottaghy, F.M.

In: Methods, Vol. 55, No. 3, 01.01.2011, p. 238-45.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - I-131-MIBG therapies

AU - Voo, S.

AU - Bucerius, J.

AU - Mottaghy, F.M.

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. Extensive work has been addressed to develop I-131-MIBG therapy: doses, therapeutic schemes, and efficiency. In this paper, we present an overview on I-131-MIBG therapy, with main focus on different aspects how to perform this treatment.

AB - Metaiodobenzylguanidine (MIBG) is a tracer that selectively targets neuroendocrine cells. On this basis, radiolabeled iodinated-MIBG (I-131-MIBG) has been introduced as a molecular nuclear therapy in the management of neuroendocrine tumors, including neuroblastoma, pheochromocytoma, paraganglioma, neuroendocrine carcinomas, and other rare neuroendocrine tumors. Extensive work has been addressed to develop I-131-MIBG therapy: doses, therapeutic schemes, and efficiency. In this paper, we present an overview on I-131-MIBG therapy, with main focus on different aspects how to perform this treatment.

U2 - 10.1016/j.ymeth.2011.10.006

DO - 10.1016/j.ymeth.2011.10.006

M3 - Article

VL - 55

SP - 238

EP - 245

JO - Methods

JF - Methods

SN - 1046-2023

IS - 3

ER -